Found: 848
Select item for more details and to access through your institution.
Hyperprogression after nivolumab for the treatment of melanoma.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2023, v. 89, n. 4, p. 616, doi. 10.25259/IJDVL_160_2021
- By:
- Publication type:
- Article
Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma.
- Published in:
- Archives of Dermatological Research, 2022, v. 314, n. 9, p. 887, doi. 10.1007/s00403-021-02305-z
- By:
- Publication type:
- Article
Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up.
- Published in:
- Urologia Internationalis, 2022, v. 106, n. 6, p. 623, doi. 10.1159/000520652
- By:
- Publication type:
- Article
NAVIGATING THE COMPLEX LANDSCAPE OF STAGE 4 PULMONARY ADENOCARCINOMA: A CAPTIVATING FIVE-YEAR SAGA OF TARGETED CARE AND VIGILANT FOLLOW-UP.
- Published in:
- Acta Marisiensis. Seria Medica, 2024, v. 70, p. 212
- By:
- Publication type:
- Article
21<sup>st</sup> INTERNATIONAL SYMPOSIUM AND SUMMER SCHOOL ON BIOANALYSIS (21STISSSB) BOOK OF ABSTRACTS.
- Published in:
- Acta Marisiensis. Seria Medica, 2023, v. 69, p. 1
- Publication type:
- Article
Zastosowanie powtórnej immunoterapii po leczeniu uzupełniającym u 47-letniego chorego na czerniaka skóry w wyjściowym stadium IIC.
- Published in:
- Forum Dermatologicum, 2022, v. 8, n. 1, p. 36, doi. 10.5603/FD.2022.0012
- By:
- Publication type:
- Article
Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab.
- Published in:
- Tomography: A Journal for Imaging Research, 2022, v. 8, n. 3, p. 1363, doi. 10.3390/tomography8030110
- By:
- Publication type:
- Article
Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency.
- Published in:
- Cold Spring Harbor Molecular Case Studies, 2021, v. 7, n. 5, p. 1, doi. 10.1101/mcs.a006129
- By:
- Publication type:
- Article
Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
- Published in:
- Modern Rheumatology Case Reports, 2023, v. 7, n. 2, p. 416, doi. 10.1093/mrcr/rxad007
- By:
- Publication type:
- Article
Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Erratum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany.
- Published in:
- Journal of Market Access & Health Policy, 2021, v. 9, n. 1, p. 1, doi. 10.1080/20016689.2020.1861804
- By:
- Publication type:
- Article
Giant cell arteritis and therapeutic response: a dual facet of immunotherapy in metastatic clear cell renal carcinoma.
- Published in:
- Oxford Medical Case Reports, 2024, v. 2024, n. 7, p. 1, doi. 10.1093/omcr/omae082
- By:
- Publication type:
- Article
P8‐172: A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 355, doi. 10.1111/resp.14150_684
- Publication type:
- Article
P8‐144: Prognostic value of neutrophil‐to‐lymphocyte ratio in patients of malignant pleural mesothelioma treated with nivolumab.
- Published in:
- Respirology, 2021, v. 26, p. 344, doi. 10.1111/resp.14150_656
- Publication type:
- Article
P8‐137: Association of immune‐related adverse events with therapeutic response to nivolumab in patients with malignant pleural mesothelioma.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_649
- Publication type:
- Article
P8‐136: Nivolumab for malignant mesothelioma: A real‐word experience.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_648
- Publication type:
- Article
P8‐119: An autopsy case of immune‐related severe colitis consequent to long‐term treatment with nivolumab in a patient with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 334, doi. 10.1111/resp.14150_631
- Publication type:
- Article
P8‐104: The clinical outcomes of nivolumab plus ipilimumab combined with platinum‐based chemotherapy, single‐center, retrospective analysis.
- Published in:
- Respirology, 2021, v. 26, p. 329, doi. 10.1111/resp.14150_616
- Publication type:
- Article
P8‐82: CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 319, doi. 10.1111/resp.14150_594
- Publication type:
- Article
P8‐34: The relation between immune‐related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 300, doi. 10.1111/resp.14150_546
- Publication type:
- Article
P8‐172: A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 355, doi. 10.1111/resp.14150_684
- Publication type:
- Article
P8‐144: Prognostic value of neutrophil‐to‐lymphocyte ratio in patients of malignant pleural mesothelioma treated with nivolumab.
- Published in:
- Respirology, 2021, v. 26, p. 344, doi. 10.1111/resp.14150_656
- Publication type:
- Article
P8‐137: Association of immune‐related adverse events with therapeutic response to nivolumab in patients with malignant pleural mesothelioma.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_649
- Publication type:
- Article
P8‐136: Nivolumab for malignant mesothelioma: A real‐word experience.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_648
- Publication type:
- Article
P8‐119: An autopsy case of immune‐related severe colitis consequent to long‐term treatment with nivolumab in a patient with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 334, doi. 10.1111/resp.14150_631
- Publication type:
- Article
P8‐104: The clinical outcomes of nivolumab plus ipilimumab combined with platinum‐based chemotherapy, single‐center, retrospective analysis.
- Published in:
- Respirology, 2021, v. 26, p. 329, doi. 10.1111/resp.14150_616
- Publication type:
- Article
P8‐82: CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 319, doi. 10.1111/resp.14150_594
- Publication type:
- Article
P8‐34: The relation between immune‐related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 300, doi. 10.1111/resp.14150_546
- Publication type:
- Article
First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy.
- Published in:
- BJU International, 2024, v. 134, n. 3, p. 323, doi. 10.1111/bju.16336
- By:
- Publication type:
- Article
NICE Guidance – Nivolumab for previously treated advanced renal cell carcinoma.
- Published in:
- BJU International, 2018, v. 122, n. 3, p. 362, doi. 10.1111/bju.14482
- Publication type:
- Article
Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 01, doi. 10.3389/fimmu.2023.1131448
- By:
- Publication type:
- Article
Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME).
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 01, doi. 10.3389/fimmu.2023.1104753
- By:
- Publication type:
- Article
Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renalcell carcinoma: A case report and review of literature.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.993622
- By:
- Publication type:
- Article
PD-L1<sup>+</sup> neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.962669
- By:
- Publication type:
- Article
Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.860421
- By:
- Publication type:
- Article
Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.908558
- By:
- Publication type:
- Article
Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.892250
- By:
- Publication type:
- Article
Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD‐1/PD‐L1‐refractory Merkel cell carcinoma—a case report.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 2, p. e69, doi. 10.1111/ijd.16986
- By:
- Publication type:
- Article
Linear IgA/IgG bullous dermatosis after nivolumab therapy.
- Published in:
- International Journal of Dermatology, 2021, v. 60, n. 8, p. 1007, doi. 10.1111/ijd.15627
- By:
- Publication type:
- Article
Pityriasis rubra pilaris induced by PD‐1 inhibitor nivolumab.
- Published in:
- International Journal of Dermatology, 2021, v. 60, n. 8, p. 1038, doi. 10.1111/ijd.15563
- By:
- Publication type:
- Article
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
- Published in:
- Cancer Research & Treatment, 2023, v. 55, n. 2, p. 636, doi. 10.4143/crt.2022.343
- By:
- Publication type:
- Article
Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 4, p. 323, doi. 10.3322/caac.21835
- By:
- Publication type:
- Article
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42400-5
- By:
- Publication type:
- Article
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40028-z
- By:
- Publication type:
- Article
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39383-8
- By:
- Publication type:
- Article